Kennedy Jr., who was tapped to lead the Department of Health and Human Services for the Trump administration, recently ...
1h
To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...
Companies in the US, including Novo Nordisk, Boeing and Shein, are forming task forces to address the impact of Donald ...
PARIS] Ozempic-maker Novo Nordisk is planning to make more of its medicines for the US market in the country; Boeing risks a ...
Roche and Zealand reason petrelintide could deliver weight loss comparable to glucagon-like peptide 1 (GLP-1) receptor ...
The FDA says state-licensed compounding pharmacies must immediately stop making compound versions of GLP-1 drugs. Larger, national licensed facilities making compound versions of Zepbound have until ...
Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for GLP-1 weight-loss drugs. Current runners-up Viking The ...
Novo Nordisk’s semaglutide diabetes and weight loss drugs, Ozempic and Wegovy, are no longer officially in shortage in the US ...
The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback